Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Share-based Compensation: 2011-2025

Historic Share-based Compensation for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $1.8 million.

  • Niagen Bioscience's Share-based Compensation rose 138.91% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 28.67%. This contributed to the annual value of $3.7 million for FY2024, which is 23.05% down from last year.
  • As of Q3 2025, Niagen Bioscience's Share-based Compensation stood at $1.8 million, which was up 18.01% from $1.5 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Share-based Compensation high stood at $1.9 million for Q1 2022, and its period low was $735,000 during Q3 2024.
  • Its 3-year average for Share-based Compensation is $1.2 million, with a median of $1.1 million in 2023.
  • Per our database at Business Quant, Niagen Bioscience's Share-based Compensation tumbled by 34.20% in 2024 and then soared by 138.91% in 2025.
  • Over the past 5 years, Niagen Bioscience's Share-based Compensation (Quarterly) stood at $1.5 million in 2021, then declined by 9.98% to $1.3 million in 2022, then dropped by 21.79% to $1.0 million in 2023, then fell by 27.48% to $752,000 in 2024, then skyrocketed by 138.91% to $1.8 million in 2025.
  • Its Share-based Compensation was $1.8 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.1 million in Q1 2025.